Court Opinion

ID: 2666611
Source: CourtListenerOpinion
Date Created: 2014-04-04 09:06:52.948727+00
Date Added: 2024-06-11T12:04:58.395571
License: Public Domain

UNITED STATES DISTRICT COURT
                           FOR THE DISTRICT OF COLUMBIA

 CYTOLOGIC, INC.,

 and

 COLORADO STATE UNIVERSITY
 RESEARCH FOUNDATION,

        Plaintiffs,
                                                          Civil Action No. 08-978 (CKK)
 v.

 BIOPHERESIS GMBH,

 and

 BIOPHERESIS TECHNOLOGIES, INC.,

        Defendants.

                                 MEMORANDUM OPINION
                                    (January 15, 2010)

       Plaintiffs, Cytologic, Inc. and Colorado State University Research Foundation

(collectively, “Cytologic”), filed the above-captioned action challenging the actions and decision

of the Board of Patent Appeals and Interferences of the United States Patent and Trademark

Office pursuant to 35 U.S.C. § 146. Cytologic named as Defendants Biopheresis GMBH, and

Biopheresis Technologies, Inc. (collectively, “Biopheresis”). Presently before the Court is

Cytologic’s [20] Motion for Summary Judgment to Vacate Interference Pursuant to 35 U.S.C. §

135(b)(1) and Request for Oral Hearing. After a searching review of the parties’ briefing, the

administrative record, the relevant case law, and the entire record herein, the Court shall DENY

Cytologic’s [20] Motion for Summary Judgment to Vacate Interference Pursuant to 35 U.S.C. §
135(b)(1) and Request for Oral Hearing, for the reasons set forth below. Specifically, the Court

finds that the Board of Patent Appeals and Interferences (the “Board”) correctly allocated the

burden of proof with respect to Cytologic’s preliminary Section 135(b)(1) Motion and that

Cytologic is precluded from raising new arguments regarding materiality before this Court that

were not presented to the Board below.

                                       I. BACKGROUND

       As is explained in more detail below, Cytologic’s now-pending motion for summary

judgment is narrow in focus and raises only two discrete challenges to the Board’s decision

below. Consequently, much of the proceedings before the Board are not directly relevant to the

instant Memorandum Opinion. Indeed, given the Court’s ultimate resolution of Cytologic’s

motion, the Court does not herein reach the substantive merits of any of the Board’s findings of

fact in the interference proceedings. Nonetheless, in order to better understand Cytologic’s

pending motion and the arguments raised therein, it is necessary to provide a brief review of the

relevant patent and interference law as well as the general factual background of this case so that

Cytologic’s current arguments may be placed in the proper context.

       A.      Patent and Interference Background

               1.      Patent Prosecution

       The process of obtaining a patent is known as “prosecution”and begins with the filing of

an application with the Patent and Trademark Office (“PTO”). See Intervet, Inc. v. Merial Ltd.,

643 F. Supp. 2d 97, 99 (D.D.C. 2009); see generally 37 C.F.R. § 1.51. A patent application

consists of a specification of the proposed patent, including a claim or claims, an oath or

declaration, drawings as may be necessary, and the appropriate filing fee. 37 C.F.R. § 1.51(b).

                                                 2
Focusing on the specification in particular, as Judge Henry H. Kennedy, Jr. aptly explained in a

recent decision,

       [a] specification must include both a written description of the invention and an
       enablement for a claimed invention that explains the “manner and process of making
       and using [the invention], in such full, clear, concise, and exact terms as to enable
       any person skilled in the art to which it pertains . . . to make and use the same.” At
       the end of the written description and enablement, a proper specification should
       conclude with a list of “claims,” which identify the specific innovations, components
       or subparts of the invention, the applicant regards as hers. A claim is a single
       sentence description of what the applicant believes to be her invention, setting the
       boundaries of the invention the applicant wishes the PTO to examine. A single claim
       can be composed of multiple elements and/or limitations.1 Elements are the
       previously known physical components that make up the claimed invention.
       Limitations, on the other hand, usually describe the claim’s restrictions. An
       application may contain several claims, and each claim usually contains several
       restrictions. It is these claims that define the scope of patent protection.

Intervet, 643 F. Supp. 2d at 99 (internal citations omitted).

       A patent examiner then reviews the application to determine whether a patent should

issue. “On taking up an application for examination or a patent in a reexamination proceeding,

the examiner shall make a thorough study thereof and shall make a thorough investigation of the

available prior art relating to the subject matter of the claimed invention.” 37 C.F.R. §

1.104(a)(1). If the patent examiner determines that the applicant is entitled to a patent under the

law, a “Notice of Allowance” is issued. Id. § 1.311(a). If, however, the patent examiner

determines that there are deficiencies or problems with the application, the examiner will issue

an “Office Action” advising the applicant as to the “reasons for any adverse action or any

objection or requirement.” Id. § 1.104(a)(2). Upon receipt of an Office Action, an applicant may

       1
         A claim may be either independent or dependent. An independent claim stands alone
and does not refer to another claim, while a dependent claim makes express reference to one or
more previous claims and includes all of the limitations of the earlier claims, as well as the new
limitation(s) found only in the dependent claim. See 35 U.S.C. § 112.

                                                  3
amend the claims, argue as to the merits of the examiner’s findings, or both. See id. § 1.111.

This back and forth between the applicant and the patent examiner continues until a patent is

issued or a final rejection occurs.

               2.      Patent Interference Practice

       United States patent law, unlike much of the rest of the world, is premised on the

principle that the first to invent — rather than the first to file a patent application — is granted

the patent right. ROBERT L. HARMON , PATENTS AND THE FEDERAL CIRCUIT , 1151 (2009). As a

consequence of this rule, there must be a mechanism for determining who among multiple patent

applicants, or, as in this case, among an applicant and a patentee, was the first to invent the

claimed subject matter. That mechanism is known as an interference, which is a “proceeding []

principally declared to permit a determination of priority.” Minnesota Mining and Mfg. Co. v.

Norton Co., 929 F.2d 670, 674 (Fed. Cir. 1991). As is oft-repeated, “[i]nterference practice is

highly arcane and specialized,” Conservolite, Inc. v. Widmayer, 21 F.3d 1098, 1100 (Fed. Cir.

1994), and can be “virtually incomprehensible to the uninitiated,” PATENTS AND THE FEDERAL

CIRCUIT , supra p. 3, at 1152.

       “An interference exists if the subject matter of a claim of one party would, if prior art,

have anticipated or rendered obvious the subject matter of a claim of the opposing party and vice

versa.” 37 C.F.R. § 41.203. Either the patent applicant or the patent examiner may suggest an

interference. See id. § 41.202. If the Director of the PTO agrees that an interference is warranted

— i.e., that “an application is made for a patent which would interfere with any pending

application, or with any unexpired patent” — he may declare an interference and provide notice

of such declaration to the applicants, or applicant and patentee, as the case may be. 35 U.S.C. §

                                                   4
135(a); see also 37 C.F.R. § 41.203.2 The Board determines questions of priority of the

inventions and may determine questions of patentability as well. 35 U.S.C. § 135(a).

        As is relevant to the case at hand, once an interference is determined to be warranted and

notice has been provided to the parties, a period is then set for the filing of preliminary

statements and preliminary motions with the Board. Gen. Instrument Corp., Inc. v. Scientific-

Atlantic, Inc., 995 F.2d 209, 211 (Fed. Cir. 1993). “The ‘preliminary’ motions are usually a

critical part of an interference.” Id. at 212. In particular, as is of import in this case, a party may

file a preliminary motion under 35 U.S.C. § 135(b)(1). Section 135(b)(1) motions are threshold

motions that should be resolved before issues of priority and/or patentability are addressed, as

resolution in favor of the movant would end the interference proceedings. See Berman v.

Housey, 291 F.3d 1345, 1352 (Fed. Cir. 2002); see also 37 C.F.R. § 41.201.

        “[S]ection 135(b) was enforced to codify a legal principle akin to laches, imposing ‘a

statute of limitations, so to speak, on interferences so that the patentee might be more secure in

his property right.’” In re Berger, 279 F.3d 975, 982 (Fed. Cir. 2002) (quoting Corbett v.

Chisholm, 568 F.2d 759, 764-65 (C.C.P.A. 1977)). It provides that:

        [a] claim which is the same as, or for the same or substantially the same subject
        matter as, a claim of an issued patent may not be made in any application unless such
        a claim is made prior to one year from the date on which the patent was granted.

35 U.S.C. § 135(b)(1). As the Federal Circuit has explained, “[t]his provision requires an

applicant wishing to provoke an interference with an issued patent to do so by filing a claim

which is ‘for the same or substantially the same subject matter’ as a claim of the issued patent,

        2
         Pursuant to the implementing regulations, an administrative patent judge declares the
patent interference on the Director’s behalf. 37 C.F.R. § 41.203(b).

                                                   5
prior to one year from the issue date of the patent.” In re Berger, 279 F.3d at 981.

       To further its purpose of imposing a statute of limitations-like bar on interference

proceedings, “[a]mended or supplemental claims added to a pending application after the one

year anniversary of the issuance of a patent may benefit from the timely filings of original patent

claims so long as the ‘the later filed claim does not differ from an earlier claim in any ‘material

limitation.’” Sears Ecological Applications Co., LLC v. MLI Assocs., LLC, 652 F. Supp. 2d 244,

269 (N.D.N.Y. Sept. 1, 2009) (quoting In re Berger, 279 F.3d at 981); see also In re Berger, 279

F.3d at 982 (“To further that purpose, a copied claim may be entitled to the earlier effective date

of prior claims in an application only if the copied claim does not differ from the prior claims in

any material limitation.”). “The analysis focuses on the copied claim to determine whether all

material limitations of the copied claim necessarily occur in the prior claims.” In re Berger, 279

F.3d at 982. “If all material limitations of the copied claim are present in, or necessarily result

from, the limitations of the prior claims, then the copied claim is entitled to the earlier effective

filing date of those prior claims for purposes of satisfying 35 U.S.C. § 135(b).” Id.

       B.      Factual Background3

               1.      Cytologic Patent

       Cytologic was granted the patent at issue on April 30, 2002, which issued from a patent

application filed on November 20, 1999. Joint Appendix, Docket No. [25] (hereinafter “JA-1”),

Ex. P10 (Board’s Decision on Motions, dated Jan. 25, 2007) (hereinafter, “Bd. Dec.”), at 4; see

       3
        The parties do not dispute any of the specific factual findings made by the Board in the
background section of its January 25, 2007 decision, as regarding the procedural history of this
claim. Accordingly, the Court has relied on and cites primarily to the Board decision below, as
supported by the Administrative Record, in reciting the factual background of this case.

                                                   6
also id., Ex. P1 (U.S. Patent 6,379,708 B1) (hereinafter “Cytologic patent”). The Cytologic

Patent is directed to a method for enhancing an immune response by selectively removing

immune system inhibitors present in the blood. See Cytologic Patent at cols. 11-4. This is

accomplished by bringing the blood into contact with a binding partner (e.g., antibodies or

fragment of antibodies) capable of selectively binding to targeted immune system inhibitors. Id.

at. col. 5, lines 26-34. This method is believed to be effective in the treatment of some types of

cancer. See id. at col. 6, lines 15-34. In discussing Cytologic’s patent, the critical date for

purposes of 35 U.S.C. § 135(b)(1) — i.e., one year from the date on which the patent was granted

— is April 30, 2003. For convenience, the Court shall refer to this date as the “critical date.”

               2.      Biopheresis’ Patent Application

       Given the importance of clearly demarcating which relevant events occurred before the

critical date and which events occurred after, the Court divides the discussion of Biopheresis’

patent application and related events accordingly.

                       i.      Pre-critical date events.

       Biopheresis filed the patent application now at issue on November 10, 2000, Patent

Application 09/709,045. Bd. Dec. at 5. As originally filed, Biopheresis’ application contained

16 claims. Id. at 12. On January 22, 2003, the application was amended to include new claims

17-22, which the application stated “essentially correspond to” the claims of Cytologic’s patent.

Id. at 12; see also JA-1, Ex. P3 (Biopheresis Amendment and Response to Office Action, dated

Jan. 22, 2003) (hereinafter “Biopheresis Jan. 22, 2003 Amend.”), at 6.4 In particular, the parties’

       4
         Given the parties’ focus on claims 17-22, the Court limits its discussion of Biopheresis’
patent application to these claims only and does not address the patent prosecution history of the
remaining claims, which are not relevant to the parties’ arguments as presented in their briefing.

                                                  7
dispute focuses on claims 17 and 22, which read as follows:

       17.     A method of enhancing an immune response to a patient comprising:
               a.    obtaining whole blood from the patient;
               b.    separating out the plasm;
               c.    contacting the plasma with antibody specifically binding to a targeted
                     immune system inhibitor;
               d.    removing the inhibitor bound to the antibody from the plasma; and
               e.    returning the antibody-collected plasma to the patient.

       ***

       22.     The method of claim 17 wherein the targeted immune system inhibitor is
               selected from the group consisting of soluble receptors for tumor necrosis
               factors alpha and beta.

Bd. Dec. at 12-13; Biopheresis Jan. 23, 2003 Amend. at 3-4.

                      ii.     Post-critical date events.5

       July 21, 2004 Office Action. On July 12, 2004, the patent examiner issued an Office

Action rejecting Biopheresis’ claims 17-22. In so doing, the patent examiner raised two grounds

for rejection that are of particular importance to Cytologic’s present motion. To understand the

patent examiner’s rejection of claims 17-22 and Cytologic’s related argument, the Court must

       5
          The parties focus exclusively on post-critical date events beginning in July 2004 and
continuing thereafter, and the Court therefore focuses its discussion of the relevant factual
background on these events as well. The Court notes, however, that the record reflects that
between the post-critical date (i.e., April 30, 2003) and the July 21, 2004 Office Action
discussion above, Biopheresis and the patent examiner did take certain actions regarding claims
17-22. Specifically, on July 29, 2003, the patent examiner issued an Office Action rejecting
claims 17-22 under 35 U.S.C. § 103(a) as unpatentable. Bd. Dec. at 13. Biopheresis replied on
October 29, 2003, but did not make any amendments to claims 17-22. Id. The patent examiner
again rejected claims 17-22 on February 25, 2004 as unpatentable. Id. On April 16, 2004,
Biopheresis replied and made minor grammatical amendments to claims 17-22, which are not
relevant to the pending dispute. Id. at 13; see also Defs.’ Opp’n at 18, n. 6. More specifically,
Biopheresis replaced “antibody” with “antibodies” and replaced “fragment” with “fragments.”
Bd. Dec. at 13. These various communications and amendments, however, are not material to
the parties’ arguments as presented in their briefing.

                                                 8
make a brief diversion once again into substantive patent law — specifically, 35 U.S.C. § 112.

The first two paragraphs of section 112 provide, in relevant part, as follows:

       The specification shall contain a written description of the invention, and of the
       manner and process of making and using it, in such full, clear, concise, and exact
       terms as to enable any person skilled in the art to which it pertains, or with which it
       is most nearly connected, to make and use the same, and shall set forth the best mode
       contemplated by the inventor of carrying out his invention.

       The specification shall conclude with one or more claims particularly pointing out
       and distinctly claiming the subject matter which the applicant regards as his
       invention.

Perhaps somewhat unimaginatively, these paragraphs are referred to as “section 112, para. 1” and

“ section112, para. 2,” respectively. The former looks into the adequacy of the claim’s written

description while the latter considers the indefiniteness of the claim language, each of which is a

“distinct question[].” Applic. of Cormany, 476 F.2d 998, 999-1000 (C.C.PA. 1973) (“We regard

indefiniteness of claim language and inadequate support for it in the specification to be distinct

questions, and we shall therefore consider them separately, the former being a question of

compliance with the second paragraph of § 112 and the latter a question of compliance with the

first paragraph.”) (internal citations omitted).

       In this case, the patent examiner raised objections under both the first and second

paragraph of section 112 in rejecting Biopheresis’ claims 17-22. First, the patent examiner

rejected claims 17-21 (but not claim 22) for failure to comply with the written description

requirement pursuant to section 112, para. 1. JA-1, Ex. P4 (Patent Examiner’s Office Action,

dated July 12, 2004) (hereinafter “July 12, 2004 Office Action”), at 5. The patent examiner

based his rejection on the fact that the “specification does not use the term ‘targeted immune

system inhibitor,’ nor can said term be said to flow from the specification as originally filed.” Id.

                                                   9
Rather, the specification was limited to methods of removing immune inhibitors produced by

tumors. Id. The patent examiner therefore concluded that claims 17-21, which did not contain

this limitation (i.e., only immune inhibitors produced by tumors as opposed to all targeted

immune system inhibitors), should be rejected under 35 U.S.C. § 112, para. 1. Id. Importantly,

as the Board observed in its decision, “the examiner did not reject claim 22, which limited the

targeted immune system inhibitor to soluble receptors for tumor necrosis factors alpha and beta,

on this ground.” Bd. Dec. at 14.

       Second, the patent examiner rejected claims 17-22 under 35 U.S.C. § 112, para. 2, as

indefinite. July 12, 2004 Office Action at 6. The examiner reasoned that while claim 17 “recites

‘contacting the plasma with antibodies specifically binding to a targeted immune system

inhibitor,” the “specification does not use nor define the term ‘immune system inhibitor,’ hence

the metes and bounds of the claim cannot be determined.’” Id. at 7.

       Biopheresis’ October 6, 2004 Amendment. Biopheresis subsequently amended claims

17-22 on October 6, 2004. Bd. Dec. at 15; JA-1, P5 (Biopheresis Amendment and Response to

Office Action of July 12, 2004, dated Oct. 6, 2004) (hereinafter “Biopheresis Oct. 6, 2004

Amend.”). Specifically, with respect to claim 17, Biopheresis amended step (c) by revising

“contacting the plasma with antibodies specifically binding to a targeted immune system

inhibitor” to read “contacting the plasma with antibodies or antibody fragments specifically

binding to soluble cytokine receptor molecules which function as cytokine inhibitors.” Bd. Dec.

at 15; see also Biopheresis Oct. 6, 2004 Amend. at 4. In other words, the amended claim 17 read

as follows (with added language underlined and deleted language struck out):

                                                10
        17.     A method of enhancing an immune response to a patient comprising:
                      a.      obtaining whole blood from the patient;
                      b.      separating out the plasm;
                      c.      contacting the plasma with antibody or antibody
                              fragments specifically binding to a targeted immune
                              system inhibitor soluble cytokine receptor molecules
                              which function as cytokine inhibitors;
                      d.      removing the inhibitor bound to the antibody from the
                              plasma; and
                      e.      returning the antibody-collected plasma to the patient.

Biopheresis Oct. 6, 2004 Amend. at 4. Claim 22, which is dependent on claim 17, was

correspondingly revised to reflect the changes in claim 17, as follows (deleted language struck

out):

        22.     The method of claim 17 wherein the targeted immune system inhibitor is
                selected from the group consisting of soluble receptors for tumor necrosis
                factors alpha and beta.

Id. at 5; see also Bd. Dec. at 15.

        January 6, 2005 Office Action. In the next Office Action, dated January 6, 2005, the

patent examiner indicated that amended claims 17-22 were allowable. Bd. Dec. at 15; see also

JA-1, Ex. P6 (Patent Examiner’s Office Action mailed Jan. 6, 2005).

        Biopheresis’ May 6, 2005 Amendment. Thereafter, on May 6, 2005, Biopheresis filed

another amendment with the PTO, cancelling claims 1-22 and adding claims 23-41. Claims 23-

41 are patterned after the claims in Cytologic’s patent in order to provoke an interference. Bd.

Dec. at 15; see also JA-1, Ex. P7 (Biopheresis Amendment under C.F.R. § 1.116 to Office

Action of January 6, 2005, dated May 6, 2005) (hereinafter, “Biopheresis May 6, 2005 Amend.”),

at 8. To that end, Biopheresis submitted a “Suggestion of Interference,” indicating that “it

believes that its claims 23-41 interfere with claims 1-44 of the [Cytologic] patent.” JA-1, Ex. P8

                                                11
(Biopheresis Suggestion of an Interference under 37 C.F.R. 41.202, dated May 6, 2005)

(hereinafter “Suggestion of Interference”).

       Claims 23-41 have not been amended. Bd. Dec. at 15. As is of relevance to the parties’

dispute, claim 23 reads as follows:

       23.     A method of enhancing an immune response in a patient having soluble
               cytokine receptor molecules in the blood which inhibit the immune response,
               the method comprising of:
               a.     obtaining whole blood from the patient;
               b.     separating plasma from the blood;
               c.     contacting the plasma with at least one cytokine receptor inhibitor
                      selected from the group consisting of antibodies or antibody
                      fragments binding to soluble cytokine receptor molecules, and
                      cytokine molecules and epitopes thereof binding to soluble cytokine
                      receptor molecules;
               d.     removing soluble cytokine receptor molecules bound to the cytokine
                      receptor inhibitor from the plasma; and
               e.     returning the plasma from which the soluble cytokine receptor
                      molecules have been removed to the patient.

Id. at 16; Biopheresis May 6, 2005 Amend. at 2.

               3.     January 12, 2006 Interference

       On January 12, 2006, the Board declared an interference between the Cytologic patent

and the Biopheresis patent application. Bd. Dec. at 4; see also JA-1, Ex. P2 (Declaration of

Interference No. 105,413) (hereinafter, “Decl. of Interference”). The sole count was defined as

claim 1 of the Cytologic patent and claim 23 of the Biopheresis patent application. Id. at 4. In

addition, claims 1-44 of the Cytologic patent and claims 23-41 of the Biopheresis patent were

identified as corresponding to the count, which means that all of these claims are affected by the

ultimate judgment on the interference. See id.

       As is relevant to the instant Memorandum Opinion, Cytologic filed a preliminary motion

                                                 12
arguing that Biopheresis claims 23-41 are barred under section 135(b)(1). See JA-1, Ex. P9

(Cytologic Section 135(b)(1) motion, titled “Howell Substantive Motion 1,” dated Feb. 21, 2006)

(hereinafter “Section 135(b)(1) Motion”); see also Bd. Dec. at 10. Biopheresis did not file an

opposition; instead, Biopheresis filed a motion requesting that, in the event Cytologic’s Section

135(b)(1) Motion was granted, Biopheresis be permitted to substitute proposed claims 42-46 for

claims 23-41.6 Bd. Dec. at 3, 10. The Board heard oral arguments on Cytologic’s Section

135(b)(1) Motion on November 9, 2006. Id. at 4.

       On January 25, 2007, the Board issued a decision that, in relevant part, denied

Cytologic’s Section 135(b)(1) Motion. As set forth therein, the Board held, inter alia, that

Cytologic, as the moving party, bore the burden of proving that Biopheresis’ involved claims 23-

41 are barred under 35 U.S.C. § 135(b)(1) and that Cytologic had “not satisf[ied] its burden of

proving that there is a material difference between the subject matter now claimed and that

claimed prior to the § 135(b) critical date.” Id. at 17. In so doing, the Board rejected Cytologic’s

argument that “the replacement of ‘targeted immune system inhibitor’ in claim 17 (a pre-critical

date claim) with ‘soluble cytokine receptor molecules, and cytokine molecules and epitopes

thereof binding to soluble receptor molecules’ in claim 23 (a post-critical date claim) renders the

latter recitation a material limitation.” Id. at 16. Cytologic had argued that the limitation was

material because the amended language “was necessary to overcome the examiner’s [July 12,

2004] rejection, which was based on the notion that the term ‘targeted system inhibitor’ lacks

       6
         At oral argument, counsel for Biopheresis emphasized that it declined to file an
opposition to Cytologic’s Section 135(b)(1) “not [as] a concession of the merits,” but “rather to
simplify and streamline the proceedings” through amendment of its claims that “would render
unnecessary getting into many of the issues those original motions sought to raise.” JA-2, Ex.
D1 (Transcript of November 9, 2006 Oral Arguments) at 8:6-17.

                                                 13
written description in the specification, as originally filed, in violation of 35 U.S.C. § 112, para.

1.” Id. The Board did not agree, concluding that:

       [Cytologic]’s argument would have some force if claim 17 were the only pre-critical
       date claim. But that is not the case. Here, we determine that claim 22 is also a pre-
       critical date claim. Claim 22 was never rejected as being in violation of the written
       description of 35 U.S.C. § 112, para. 1. . . . In this regard, claim 22 limited the
       targeted immune system inhibitor to soluble receptors for tumor necrosis factors
       alpha and beta. [Cytologic] failed to address how and why the differences between
       any of the post-critical date claims 23-41, on one hand, and pre-critical date claim 22,
       on the other hand, constitute material differences.

       ***

       At issue is whether [Biopheresis]’s post-critical date claims, which interfere with the
       claims of [Cytologic]’s patent, are not entitled to the filing date of [Biopheresis]’s
       pre-critical date claims. If a later filed claim involved in interference does not differ
       from an earlier filed claim in any material limitation, then a rejection under 35 U.S.C.
       § 135(b)(1) of that claim is not appropriate. Here, [Cytologic] has not established
       that the differences between the post-critical date involved claims and all pre-critical
       date claims, in particular claim 22, were in fact necessary for patentability.

Id. at 17-18. The Board therefore concluded that Cytologic had failed to show that claims 23-41

were barred under section 135(b)(1). Cytologic now challenges that decision.

               4.      The Instant Lawsuit

       On June 6, 2008, Cytologic filed the above-captioned lawsuit seeking review of the

Board’s decisions in the interference pursuant to 35 U.S.C. § 146. See generally Compl., Docket

No. [1]. At the Court’s request, the parties filed a joint status report proposing a schedule for

proceeding in this matter. Jt. Status. Report, Docket No. [17]. Cytologic indicated its intent to

file a summary judgment motion under 35 U.S.C. § 135(b)(1), which, if granted, would result in

a voiding of the Board’s decision. See id. at 2. Cytologic therefore proposed that the parties

brief, and the Court resolve, the section 135(b)(1) issue before proceeding with discovery. Id. at

                                                  14
2. Biopheresis indicated that while it “[did] not object to early presentation of Plaintiffs’

proposed dispositive motion based on § 135(b),” it took the position that the parties should

proceed to brief disputes as to the scope of discovery in this case. Id. at 3-4. The Court

ultimately agreed with Cytologic’s proposed schedule and set a schedule for proceeding with

Cytologic’s motion for summary judgment on the threshold section 135(b)(1) question, deferring

consideration of discovery issues until after the motion is resolved. See 11/13/08 Order, Docket

No. [18].

       Pursuant to that schedule, Cytologic filed the now-pending Motion for Summary

Judgment to Vacate Interference Pursuant to 35 U.S.C. § 135(b)(1) and Request for Oral

Hearing. See Pls.’ MSJ, Docket No. [20]. Biopheresis filed an opposition, see Defs.’Opp’n,

Docket No. [21], and Cytologic has since filed its reply, see Pls.’ Reply, Docket No. [23]. In

addition, the parties jointly moved for an order entering the entire administrative record of the

interference proceeding below as part of the record in this case, see Docket No. [22], which the

Court granted, see 12/31/08 Min. Order. The parties have also filed their Joint Appendix of the

Administrative Record. See Docket Nos. [25] & [26]. In addition, after principal briefing had

been completed, the Court issued a minute order directing Cytologic to file a supplemental

notice, see 12/16/09 Min. Order, which notice Cytologic has timely filed, see Pls.’ Notice,

Docket No. [28]. The Court provided Biopheresis an opportunity to respond to Cytologic’s

supplemental notice and also invited Biopheresis to file a sur-reply addressing a particular

argument that Cytologic had raised for the first time in its reply, see 12/22/09 Min. Order, which

it has now done, see Defs.’ Sur-Reply. Cytologic subsequently filed an unopposed motion for

leave to file a targeted response to Biopheresis’ sur-reply, which the Court granted. See 1/15/10

                                                 15
Min. Order. Accordingly, the parties’ briefing is complete, and the matter is therefore ripe for

review and resolution by the Court.7

                                       II. LEGAL STANDARD

       A.      Summary Judgment

       Pursuant to Federal Rule of Civil Procedure 56, a party is entitled to summary judgment

“if the pleadings, the discovery and disclosure materials on file, and any affidavits show that

there is no genuine issue as to any material fact and that the movant is entitled to judgment as a

matter of law.” Fed. R. Civ. P. 56(c); see also Tao v. Freeh, 27 F.3d 635, 638 (D.C. Cir. 1994).

Under the summary judgment standard, the moving party bears the “initial responsibility of

informing the district court of the basis for [its] motion, and identifying those portions of the

pleadings, depositions, answers to interrogatories, and admissions on file, together with the

affidavits which [it] believe[s] demonstrate the absence of a genuine issue of material fact.”

Celotex Corp. v. Catrett, 477 U.S. 317, 323 (1986). In response, the non-moving party must “go

beyond the pleadings and by [its] own affidavits, or depositions, answers to interrogatories, and

admissions on file, ‘designate’ specific facts showing that there is a genuine issue for trial.” Id.

at 324 (internal citations omitted).

       Although a court should draw all inferences from the supporting records submitted by the

nonmoving party, the mere existence of a factual dispute, by itself, is insufficient to bar summary

judgment. See Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 248 (1986). To be material, the

       7
         As the Court concludes that the issues presented in Cytologic’s pending motion may be
resolved on the extensive briefing filed by the parties, an oral hearing is unnecessary and the
Court shall therefore DENY Cytologic’s request that the Court hold oral arguments on its
motion.

                                                 16
factual assertion must be capable of affecting the substantive outcome of the litigation; to be

genuine, the issue must be supported by sufficient admissible evidence that a reasonable trier-of-

fact could find for the nonmoving party. Laningham v. U.S. Navy, 813 F.2d 1236, 1242-43 (D.C.

Cir. 1987); Liberty Lobby, 477 U.S. at 251 (the court must determine “whether the evidence

presents a sufficient disagreement to require submission to a jury or whether it is so one-sided

that one party must prevail as a matter of law”). “If the evidence is merely colorable, or is not

sufficiently probative, summary judgment may be granted.” Liberty Lobby, 477 U.S. at 249-50

(internal citations omitted). “Mere allegations or denials in the adverse party’s pleadings are

insufficient to defeat an otherwise proper motion for summary judgment.” Williams v.

Callaghan, 938 F. Supp. 46, 49 (D.D.C. 1996). The adverse party must do more than simply

“show that there is some metaphysical doubt as to the material facts.” Matsushita Elec. Indus.

Co. v. Zenith Radio Corp., 475 U.S. 574, 586 (1986). Instead, while the movant bears the initial

responsibility of identifying those portions of the record that demonstrate the absence of a

genuine issue of material fact, the burden shifts to the non-movant to “come forward with

‘specific facts showing that there is a genuine issue for trial.’” Id. at 587 (citing Fed. R. Civ. P.

56(e)) (emphasis in original).

       B.      Standard of Review Under 35 U.S.C. § 146

       Cytologic seeks review of the Board’s decision in the interference proceeding below

pursuant to 35 U.S.C. § 146, see Compl. ¶ 1, which provides that “[a]ny party to an interference

dissatisfied with the decision of the Board . . . on the interference, may have remedy by civil

action,” 35 U.S.C. § 146. An action under section 146 “may be instituted against the party in

interest as shown by the records of the Patent and Trademark Office at the time of the decision

                                                  17
complained of” — in this case, Biopheresis. Id. Moreover, where, as here, there is “an adverse

party residing in a foreign country, the United States District Court for the District of Columbia

shall have jurisdiction and may issue summons against the adverse parties.” Id.

       Judicial review under section 146 is “described as a hybrid of an appeal and a trial de

novo.” Estee Lauder Inc. v. L’Oreal, S.A., 129 F.3d 588, 592 (Fed. Cir. 1997). In such actions,

the record below may be admitted by either party, but the parties may “take further testimony.”

See 35 U.S.C. § 145; see also Agilent Tech., Inc. v. Affymetrix, Inc., 567 F.3d 1366, 1379 (Fed.

Cir. 2009). “Questions of law are reviewed de novo, but the underlying factual determinations

made by the Board are reviewed for clear error.” Abbott GMBH & Co. KG v. Yeda Research &

Dev. Co, Ltd., 576 F. Supp. 2d 44, 49 (D.D.C. 2008) (citing Winner Int’l Royalty Corp. v. Wang,

202 F.3d 1340, 1348 (Fed. Cir. 2000)). If, however, the district court accepts new evidence not

previously before the Board, the Court must make de novo factual findings for issues on which

the court accepts new evidence. Id. The Court notes that for purposes of Cytologic’s pending

motion, the parties have relied solely on the administrative record and have not submitted new

evidence.

                                       III. DISCUSSION

       As indicated above, Cytologic’s pending motion for summary judgment focuses solely on

the Board’s decision to deny Cytologic’s preliminary Section 135(b)(1) Motion. The Court

emphasizes at the outset that, in challenging the Board’s decision, Cytologic has chosen not to

dispute the majority of the Board’s underlying findings of fact and conclusions of law as set forth

in the Board’s lengthy discussion of Cytologic’s Section 135(b)(1) Motion. See Bd. Dec. at 10-

23 (portion of the Board Decision discussing Cytologic’s Section 135(b)(1) Motion). Cytologic

                                                18
has instead presented a very narrow and targeted challenge to the Board’s decision. Specifically,

Cytologic argues that the Board’s decision is in error for only two discrete reasons, as outlined

below, either of which Cytologic asserts require reversal of the Board’s decision and final

judgment in favor of Cytologic. The Court’s discussion is therefore similarly limited in scope,

addressing only the two specific Board rulings that Cytologic now claims are in error.

       First, Cytologic argues that the Board erroneously allocated the burden of proof with

respect to the question of materiality under section 135(b)(1). According to Cytologic, in order

to succeed on its Section 135(b)(1) Motion, it needed to show only that Biopheresis claims 23-41

— which formed the basis of the interference proceedings — were filed more than one year after

Cytologic’s patent was issued. Once this showing was made, Cytologic had demonstrated that

the claims were barred under section 135(b)(1) absent proof by Biopheresis that claims 23-41 did

not differ in any material limitation from its pre-critical date claims 17-22, such that the claims

could benefit from the earlier filing date. Because Biopheresis did not file an opposition to

Cytologic’s Section 135(b)(1) Motion, Cytologic contends that Biopheresis failed to meet its

burden of proof with respect to materiality and the Board should have found that claims 23-41

were therefore barred under section 135(b)(1). For the reasons set forth below, the Court

ultimately finds that Cytologic’s argument lacks merit and concludes that the Board correctly

held that Cytologic — and not Biopheresis — bore the burden of demonstrating that Biopheresis

claims 23-41 differed in a material limitation from claims 17-22.

       Second, Cytologic argues that even if the Board properly allocated the burden of proof,

the Board nonetheless erred when it held that Cytologic had not demonstrated that claims 23-41

differed in a material limitation from claims 17-22 because it ignored a key fact in reaching this

                                                 19
determination — namely, that the patent examiner rejected claims 17-22 under section 112, para.

2. Cytologic contends that the patent examiner’s rejection of the claims under section 112, para.

2 conclusively demonstrates that the claims differ in a material limitation, and the Board

therefore acted in error when it failed to consider the effect of the section 112, para. 2 rejection in

denying Cytologic’s Preliminary Section 135(b)(1) Motion. As is discussed in more detail

below, the Court finds that Cytologic did not present this specific argument to the Board and is

therefore precluded from doing so now.

       A.      Burden of Proof

       First, Cytologic argues that the Board erred when it required Cytologic to bear the burden

of proving that Biopheresis’ involved claims (23-41) materially differed from its pre-critical date

claims (17-22). According to Cytologic, it should have been required to show only that

Biopheresis claims 23-41 had been filed after the critical date — i.e., more than one year after

Cytologic’s patent had been issued — and that once this showing was made, the burden then

shifted to Biopheresis to show that these claims do not differ materially from the earlier claims

(17-22), such that they may benefit from the earlier filing date pursuant to section 135(b)(1).

Pls.’ MSJ at 7-8. Because Biopheresis chose not to file an opposition to Cytologic’s motion, but

instead filed a motion seeking leave to file further amendments to the claims, Cytologic argues

that Biopheresis clearly failed to meet its burden, and the Board therefore should have granted

Cytologic’s section 135(b) motion. Id. at 8.

       As the Court understands Cytologic’s argument, it does not dispute the Board’s holding

pursuant to 37 C.F.R. § 41-121(b) that Cytologic, “[a]s the moving party, [] bears the burden of

proving that [Biopheresis]’s involved claims 23-41 are barred under U.S.C. § 135(b)(1).” Bd.

                                                  20
Dec. at 10. Nor could it, as the regulations make clear that Cytologic, as the movant, properly

bore the burden of proof to show that it was entitled to the remedy requested. Specifically, 37

C.F.R. § 41.121(b) provides that “[t]he party filing the motion has the burden of proof to

establish that it is entitled to the requested relief.”8 In addition, although not cited by the Board,

37 C.F.R.§ 41.208(b) — which governs the requirements for substantive motions filed in patent

interferences (as opposed to contested cases in general) and serves to supplement the general

requirements for motions filed in contested cases as set forth in 37 C.F.R. § 41.121 — further

specifies that, “[t]o be sufficient, a motion must provide a showing, supported with appropriate

evidence, such that, if unrebutted, it would justify the relief sought. The burden of proof is on

the movant.” 37 C.F.R. § 41.208(b).

       Rather, it appears that Cytologic disagrees only as to what showing it was required to

make in order to meet that burden of proof. Specifically, the Board held that Cytologic, as the

movant, had the burden to show not only that the involved claims (23-41) were filed after the

post-critical date — a fact that is undisputed — but also that those claims materially differed

from the pre-critical date claims 17-22. See Bd. Dec. at 17 (“[Cytologic’s] assertion does not

satisfy its burden of proving that there is a material difference between the subject matter claims

now and that claimed prior to the § 135(b) critical date.”). Cytologic disagrees, arguing that it

should have been required to prove only that Biopheresis’ involved claims (23-41) were filed

after the post-critical date. According to Cytologic, once it made that showing, it satisfied its

       8
        While section 41.121(b) explicitly applies only to “contested cases,” the regulations
make clear that “[a] patent interference is a contested case” and is therefore subject to the general
procedures governing contested cases, including the procedures set forth in 37 C.F.R. §
41.121(b). 37. U.S.C. § 41.200(a).

                                                  21
burden of proof under section 135(b)(1), and it was then up to Biopheresis, as the patent

applicant, to show that its post-critical date claims are nonetheless permissible because they do

not materially differ from pre-critical date claims. Pls.’ MSJ at 7-8. The Court, however, does

not agree. As explained below, the Court finds that the Board correctly held that Cytologic, as

the movant, was required to prove that Biopheresis’ post-critical date claims were barred by

section 135(b)(1) — which necessarily included demonstrating that the claims contained a

material limitation not found in the pre-critical date claims, such that they could not benefit from

the earlier claims’ pre-critical date filing.

        As an initial matter, there is no dispute that a patent applicant who seeks declaration of an

interference based on claims filed after the relevant critical date — i.e., more than a year after the

issuance of the patent at issue — bears the burden in the first instance of demonstrating that its

late-filed claims are not barred by section 135(b)(1). As Biopheresis argues, and as Cytologic

does not dispute, the party initially requesting the interference must demonstrate that it is entitled

to priority of claims, and the patent examiner must be satisfied that the conditions for an

interference have been met. See Defs.’ Opp’n at 10-11. Accordingly, in this case, it is

undisputed that Biopheresis initially bore the burden of proving to the patent examiner that its

late filed claims (23-41) do not differ in any material limitation from its timely claims (17-22),

such that section 135(b)(1) did not bar the examiner from declaring an interference in the first

instance based on Biopheresis claims 23-41.

        Once an interference has been declared, however, the parties disagree as to who bears the

burden of showing materiality (or immateriality) when a preliminary section 135(b)(1) motion is

filed during interference proceedings. Cytologic argues that the patent applicant at all times

                                                  22
retains the burden of showing an absence of materiality, while Biopheresis takes the position

that, once an interference has been declared, the party seeking to challenge that decision through

a section 135(b)(1) motion bears the burden of proving materiality. Neither party has provided

the Court with any case law directly addressing the question of the burden of proof under 37

C.F.R. § 41.121(b) when a party files a section 135(b)(1) motion during an interference

proceeding, nor is the Court aware of any such authority. Although Cytologic cites to the

decision in Regents of the University of California v. University of Iowa Research Foundation,

455 F.3d 1371 (Fed. Cir. 2006), that opinion does not specifically discuss or address a party’s

burden of proof on a preliminary section 135(b)(1) motion after an interference has been

declared. Similarly, Cytologic relies heavily on Parks v. Fine, 773 F.2d 1577 (Fed. Cir. 1985),

but that decision makes no reference to the current regulatory scheme specifically allocating the

burden of proof on the party proponent and indeed was decided well before the relevant

regulations regarding the burden of proof took effect. The particular question at hand thus

appears to be an issue of first impression.

       Nonetheless, Cytologic maintains that Parks governs the outcome of this Court’s decision

— notwithstanding that Cytologic concedes the decision was issued well before the current

regulations were promulgated. Citing to the well established principle that the PTO lacks

substantive rulemaking authority to overturn legal precedent, Cytologic argues that the PTO was

without authority to issue regulations contradicting the holding in Parks and therefore, to the

extent the holding in Parks differs from the current regulations, the decision in Parks controls.

See Pls.’ Sur-Surreply at 1-2 (citing Koniklijke Philips Elec. N.V. v. Cardiac Sci. Operating Co.,

__ F.3d __, Civ. Act. No. 2009-1241, 2010 WL 10913 (Fed. Cir. Jan. 5, 2010); Agilent Tech.,

                                                23
Inc. v. Affymetrix, Inc., 567 F.3d 1366 (Fed. Cir. 2009); Wyeth v. Kappos, __ F.3d __, Civ. Act.

No. 2009-1120, 2010 WL 27184 (Fed. Cir. Jan. 7, 2010)). This argument is without merit. As

the cases cited by Cytologic make clear, although the PTO does not have authority to issue

substantive rules, it does have the authority to issue “procedural regulations regarding the

conduct of proceedings before the agency.” Wyeth, 2010 WL 27184, at *3 (internal quotations

marks omitted) (emphasis added); see also Merck & Co., Inc. v. Kessler, 80 F.3d 1543, 1549-50

(Fed. Cir. 1996) (PTO Commissioner is authorized “to promulgate regulations directed only to

‘the conduct of proceedings in the [PTO];’ it does NOT grant the Commission the authority to

issue substantive rules”) (quoting Animal Legal Defense Fund v. Quigg, 932 F.2d 920, 930 (Fed.

Cir. 1991)). As regulations governing the burden of proof during interference proceedings are

procedural — not substantive — the PTO was therefore well within its authority to issue the

regulations at issue. Cf. Mahurkar v. C.R. Bard, Inc., 79 F.3d 1572, 1576 (Fed. Cir. 1996)

(describing rules regarding burden of proof in the interference proceeding as procedural in

nature); Kubota v. Shibuya, 999 F.2d 517, 521 (Fed. Cir. 1993) (discounting precedent decided

under the old interference rules and upholding PTO’s issuance of new regulations that changed

burden of proof in interference proceedings). The Court therefore rejects Cytologic’s position

that the holding in Parks governs the specific question at issue in this case.

       The issue presented by the parties thus appears to be one of first impression and neither

party has directed the Court to any binding precedent that governs resolution of this question.

The Court, however, is not without guidance. Careful review of the relevant case law and the

present regulatory scheme persuade the Court that Biopheresis has the better argument, for the

reasons set forth below.

                                                 24
        As discussed above, the regulations make clear that “[t]he party filing the motion has the

burden of proof to establish that it is entitled to the requested relief,” 37 C.F.R. § 41.121(b), and

that, “[t]o be sufficient, a motion must provide a showing, supported with appropriate evidence,

such that, if unrebutted, it would justify the relief sought,” id. § 41.208(b). In this case,

Cytologic’s preliminary Section 135(b)(1) Motion sought to prove that Biopheresis’ later filed

claims were time barred pursuant to that section, such that the interference should be dissolved.

Where, as here, the claims at issue are supplemental or amended claims filed more than one year

after the challenged patent was granted, section 135(b)(1) as construed by the relevant case law

bars such claims unless they are “entitled to the earlier effective date of prior claims in an

application.” In re Berger, 279 F. 3d at 982. Whether a post-critical date claim may benefit

from the earlier filing date in turn depends upon showing that the later filed claim does not differ

from an earlier claim in any “material limitation.” Id. “If all material limitations of the copied

claim are present in, or necessarily result from, the limitations of the prior claims, then the copied

claim is entitled to the earlier effective filing date of those prior claims for purposes of satisfying

35 U.S.C. § 135(b).” Id. In other words, post-critical date claims are entitled to the earlier filing

date of pre-critical date claims and are not barred by section 135(b) if they “do[] not differ from

the prior claims in any material limitation.” Id. From this flows the eminently reasonable

conclusion that in order to show that it was entitled to the relief sought — i.e., that Biopheresis’

post-critical date claims (23-41) are barred under section 135(b)(1) — Cytologic was required to

prove that those claims could not benefit from the earlier filing date of the pre-critical claims. In

order to do so, Cytologic had to show that the post-critical date claims differed from the earlier

filed claims (17-22) in a material limitation. It was not enough to simply point the Board to the

                                                  25
undisputed fact that Biopheresis’ post-critical date claims were filed more than one year after

Cytologic’s patent was granted. Case law makes clear that such claims may nonetheless serve as

the basis for an interference if they do not differ in a material limitation from Biopheresis’ timely

pre-critical date claims.

       Cytologic’s argument to the contrary appears to be based on the premise that because the

statute itself “does not contain any language regarding material differences between post- and

pre-critical date claims,” Cytologic needed to prove only that the Biopheresis’ claims were filed

after the critical date as set forth in section 135(b)(1) in order to show that the claims are time

barred under the statute. Pls.’ MSJ at 7-8. But this line of reasoning ignores well established

case law construing section 135(b)(1) to bar only those amended or supplemental claims that

differ from previous, timely claims in a material limitation. Just as a proponent seeking to

provoke an interference bears the burden of proving that a later filed claim does not materially

differ from an earlier filed claim, a proponent seeking to dissolve an interference based on

section 135(b)(1) bears the burden of proving that a later filed claim does materially differ from

an earlier filed claim. Indeed, Cytologic’s position that the movant seeking to dissolve an

interference proceeding pursuant to section 135(b)(1) need only show that the involved claims

were filed after the one year critical date makes little sense. As discussed above, the patent

examiner must be satisfied that the conditions for an interference have been met before an

interference is declared. This in turn requires that the party requesting the interference

sufficiently demonstrate that any claims filed after the one year critical date are able to benefit

from the earlier filing date of prior claims, such that they are not barred by section 135(b)(1). It

would be far from efficient or logical if the interference could then be dissolved simply upon a

                                                  26
showing that the involved claims were filed after the one year critical date — a fact of which all

parties and the Board are surely aware.

       A review of recent case law supports this conclusion. Although, as discussed above,

neither the parties nor the Court has identified a case in which the parties directly litigated the

specific question at hand, at least one court has proceeded on the understanding — accepted by

all parties — that the party moving for dissolution of an interference pursuant to section

135(b)(1) bears the burden of proving “that the pre-critical date claims did not include the same

material limitations stated within the post-critical date claims.” Sears Ecological Applications,

652 F. Supp. 2d at 270. Moreover, recent decisions by the Federal Circuit confirm the general

trend under the new PTO regulatory scheme to require the party seeking to dissolve an

interference to bear the burden of showing that it is entitled to the requested relief. See, e.g.,

Conservolite, Inc. v. Widmayer, 21 F.3d 1098, 1101 (Fed. Cir. 1994) (“once an interference has

been declared, the burden is on a party who seeks to change the nature of the interference to take

action by means of a suitable motion to persuade the examiner-in-chief or the Board of the merits

of his or her position”); Kubota, 999 F.2d at 522 (“It seems to us that, while the burden initially

may be on a party seeking to provide an interference, or seeking to obtain entitlement to a priority

date, once an interference has been declared and a party seeks to change the status of the parties

by motion, the burden is then on the movant under the new rules, rather than on the party

originally provoking the interference or obtaining entitlement.”); Bilstad v. Wakalopulos, 386

F.3d 1116, 1121 (Fed. Cir. 2004) (“Thus, once [the party seeking to provoke an interference]

convinced the examiner he was entitled to an interference, that decision was presumed to be

correct, and [the party seeking to dissolve the interference] bore the burden of proving that it was

                                                  27
incorrect by a preponderance of the evidence.”). Although, as Cytologic notes, these cases

involve different preliminary substantive motions and do not directly address the burden of proof

in filing a preliminary section 135(b)(1) motion, the logic behind these decisions is persuasive

and further supports finding that Cytologic bore the burden of showing that the interference was

wrongly invoked in the first instance. In order to do so, Cytologic was required to show that

Biopheresis’ later filed claims did not in fact benefit from the timely filing date of its earlier

claims. Accordingly, the Court finds that the Board correctly held that Cytologic — and not

Biopheresis — bore the burden of demonstrating that Biopheresis claims 23-41 differed in a

material limitation from claims 17-22. Cytologic’s motion is therefore DENIED to the extent it

argues that the Board incorrectly allocated the burden of proof with respect to Cytologic’s

preliminary Section 135(b)(1) Motion.

        B.      Materiality Under Section 135(b)(1)

        Second, Cytologic contends that even if the Board properly held that it bore the burden of

proof on materiality, Cytologic nonetheless demonstrated that Biopheresis claims 23-41 differed

in a material limitation from claims 17-22, and the Board therefore erred when it found to the

contrary. Cytologic’s argument on this point is a narrow one. Specifically, Cytologic argues that

the Board erroneously “neglected to consider” that claim 22 had been rejected by the patent

examiner for being indefinite under 35 U.S.C. § 112, para. 2. Pls.’ MSJ at 9. Unfortunately for

Cytologic, it did not present this specific argument to the Board in the interference proceedings

below and is therefore foreclosed from doing so now.

        With respect to the issue of materiality, Cytologic argued in its preliminary Section

135(b)(1) Motion that Biopheresis claim 17 differed from Biopheresis claim 23 in a material

                                                  28
limitation because the former contained the phrase “targeted immune system inhibitor” while the

latter had been amended to replace that language with the phrase “soluble cytokine receptor

molecules, and cytokine molecules and epitopes thereof binding to soluble receptor molecules.”

Section 135(b)(1) Mot. at 11. According to Cytologic, because Biopheresis amended the

language in claim 23 in order to address the patent examiner’s rejection of claim 17 “as not

supported by the specification” under section 112, para. 1, the amendment was “necessary for

patentability” and therefore material under Federal Circuit case law. Id. at 11. Cytologic’s

materiality argument thus focused on the fact that Biopheresis had added the phrase “soluble

cytokine receptor molecules” to claim 23 in response to the patent examiner’s rejection of claim

17 under to section 112, para. 1 (written description). See id.

       Cytologic’s materiality argument was thus based solely on the patent examiner’s section

112, para. 1 (written description) rejection. Cytologic did not raise a similar materiality

argument based on the patent examiner’s rejection under section 112, para. 2 (indefiniteness).

See id. When asked to provide the Court with record citations to any discussion of section 112,

para. 2 in its briefing below, Cytologic responded that it had “raised that argument at page 11,

lines 11-20 of the [] Section § 135(b)(1) Motion before the Board.” Pls.’ Not. at 1. The cited

portion of Cytologic’s Section 135(b)(1) Motion, however, does not contain any discussion of

section 112, para. 2 or of the patent examiner’s rejection of claims 17-22 as indefinite — but

instead refers only to section 112, para. 1 and the patent examiner’s rejection of claim 17 as “not

supported by the specification.” See Section 135(b)(1) Mot. at 11. The relevant provision of

Cytologic’s brief below states in full:

       The Examiner of [Biopheresis] Claim 17 required removal of the recitation of

                                                 29
       “targeted immune system inhibitor” from the claim, because it was not supported by
       the specification. (Material Fact 39). In Claim 23, [Biopheresis] replaced the
       recitation of “targeted immune system inhibitor” used in Claim 17 with “soluble
       cytokine receptor molecules, and cytokine molecules and epitopes thereof binding
       to soluble receptor molecules.” (Material Fact 40). The phrase added to Claim 23
       of “soluble receptor molecules” is a material limitation compared to “targeted
       immune system inhibitor” which was recited in [Biopheresis] Claim 17, because it
       was an amendment necessary for patentability. Only upon adding Claims 23-41 and
       canceling Claims 17-22 over the claims found to be reliable. (See also Material Fact
       41).

See id. at 11 (lines 11-20). As careful review of this passage confirms, Cytologic’s argument in

its briefing below was based solely on the patent examiner’s rejection of claim 17 as “not

supported by the specification” — a section 112, para. 1 written description argument. The

briefing makes no mention of, nor includes any argument based on, the patent examiner’s

rejection of claims 17-22 under section 112, para. 2 for indefiniteness. See id. Similarly, the

specific statements of material fact cited to in the quoted passage focus solely on the patent

examiner’s rejection of claim 17 as “not supported by the specification,” and contain no facts

relating to the patent examiner’s section 112, para. 2 rejection for indefiniteness. See id., App. B,

¶¶ 39-41.

       Cytologic’s only argument to the Board, then, was its contention that Biopheresis’ post-

and pre-critical date claims differed in a material limitation because the phrase “soluble cytokine

receptor molecules” was added to claim 23 in order to overcome the patent examiner’s rejection

of claim 17 under section 112, para. 1 rejection. The Board ultimately rejected this argument,

finding that claim 22 was also a pre-critical date claim and that it, unlike claim 17, had not been

rejected by the patent examiner under section 112, para. 1. Because Cytologic’s argument with

respect to the patent examiner’s section 112, para. 1 rejection did not apply to claim 22 and

                                                 30
Cytologic had not presented any alternative argument addressing claim 22 in particular, the

Board held that Cytologic had failed to prove that Biopheresis’ post-critical date claims are not

entitled to claim 22’s earlier filing date. See Bd. Dec. at 17-18. Given that Cytologic presented

the Board with an argument based on the patent examiner’s rejection of claim 22 under section

112, para. 2, it is difficult to understand how the Board erred, as Cytologic contends, when it

“neglected to consider” that very argument — an argument that was never before it. Regardless,

Cytologic’s failure to raise any such argument in the interference proceedings is fatal to its efforts

to do so now.

       Case law makes clear that a party may not raise new issues on appeal that were not fully

presented at the Board level. Conservolite, 21 F.3d at 1102; see also In re Watts, 354 F.3d 1362,

1367-68 (Fed. Cir. 2004). “In a proceeding before the Board the applicant is given a full

‘opportunity to bring forth the facts thought necessary to support his or her position.’” In re

Watts, 354 F.3d at 1367 (quoting In re Gartside, 203 F.3d 1305, 1314 (Fed. Cir. 2000)). “[T]he

parties to an interference must make complete presentation of the issues at the Board level so that

the interference is efficient and not wasteful of administrative and judicial resources.”

Conservolite, 21 F.3d at 1102. Thus, while “Section 146 authorizes the district court on review

to accept new testimony,” such testimony must relate to “issues raised by the parties during the

proceedings below or by the Board’s decision.” Id. “In order for an issue to be raised adequately

in an interference proceeding so that it qualifies for evidentiary review in a section 146

proceeding, more is required than passing reference to the subject during the course of the

interference proceeding. For the most part, parties should raise issues in the manner clearly

specified in the PTO’s interference regulations, that is through preliminary motions, motions to

                                                 31
correct inventorship, belated motions delayed for good cause or opposition to these motions.”

Gen. Instrument Corp., Inc. v. Scientific-Atlanta, Inc., 995 F.2d 209, 214 (Fed. Cir. 1993).

       Here, Cytologic did not raise any materiality argument regarding the patent examiner’s

rejection of claims 17-22 under section 112, para. 2 at Board level. Although Cytologic

generally argued that Biopheresis’ post-critical date claims are barred under section 135(b)(1)

because they contain material limitations not present in Biopheresis’ pre-critical date claims, its

failure to raise the specific argument now at issue precludes consideration of that argument in

this section 146 action. See Sears Ecological Applications, 652 F. Supp. 2d at 271 (“Although

the overarching issue of whether [defendant]’s post-critical date claims relate back to its pre-

critical date claims was presented before the Board, [plaintiff]’s failure to raise an argument at

the Interference with respect to [a particular] limitation issue bars present consideration of that

argument in this § 146 action.”). Accordingly, Cytologic’s motion is DENIED to the extent it

argues that the Board erred when it failed to consider the patent examiner’s indefiniteness

rejection of claim 22 under 35 U.S.C. § 112, para. 2 (indefiniteness).

                                       IV. CONCLUSION

       For the reasons set forth above, Cytologic’s [20] Motion for Summary Judgment to

Vacate Interference Pursuant to 35 U.S.C. § 135(b)(1) and Request for Oral Hearing is DENIED.

An appropriate Order accompanies this Memorandum Opinion.

Date: January 15, 2010

                                                       /s/
                                                       COLLEEN KOLLAR-KOTELLY
                                                       United States District Judge

                                                 32